title: Survival and quality of life in 23 patients with severe aplastic anemia treated with bone marrow transplantation (BMT).
abstract: Survival and quality of life are reported in 23 pretransfused patients with severe aplastic anemia (SAA) who underwent bone marrow transplantation (BMT). The projected survival is 76% with 18 of 23 patients being alive 332 to 1677 days post graft (median: 842). 5 patients died between day 4 and 416. 12 of 17 patients at risk developed chronic graft versus host disease (GVH-D). 4 of these patients have a diminished quality of life due GVH-D related disabling manifestations. Autologous haemopoietic recovery was excluded in all patients by the demonstration of haemopoietic chimerism. We recommand age-adapted rejection prophylaxis; such strategy may help to diminish disabling graft versus host disease in otherwise haematologically reconstituted survivors.
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000401:mortality* / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006410:Hematopoiesis; D006801:Humans; D010356:Patient Isolation; D011788:Quality of Life
chemical_list: D000900:Anti-Bacterial Agents; D003520:Cyclophosphamide